Remicade Biosimilar Market Growth Outlook Through 2024-2033

Overview and Scope
Remicade biosimilar refers to a biological drug like Remicade used to treat certain autoimmune diseases in adults and children. It treats autoimmune inflammatory conditions like psoriasis, rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.

Sizing and Forecast
The remicade biosimilar market size has grown exponentially in recent years. It will grow from $3.2 billion in 2023 to $3.99 billion in 2024 at a compound annual growth rate (CAGR) of 24.4%. The growth in the historic period can be attributed to introduction of remicade (infliximab), biotechnology advancements, biologics patent expiry, regulatory pathway establishment, healthcare cost pressures.

The remicade biosimilar market size is expected to see exponential growth in the next few years. It will grow to $9.1 billion in 2028 at a compound annual growth rate (CAGR) of 22.9%. The growth in the forecast period can be attributed to patent expirations, rising demand for cost-effective therapies, biosimilar pipeline development, reimbursement policies, market consolidation. Major trends in the forecast period include physician prescribing behavior, biosimilar lifecycle management, biosimilar naming conventions, biosimilar interchangeability, biosimilar real-world evidence.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

Segmentation & Regional Insights
The remicade biosimilar market covered in this report is segmented –

1) By Type: 100mg/10ml, 500mg/50ml
2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Psoriatic Arthritis, Plaque Psoriasis
3) By Application: Blood Disorders, Oncology Diseases

Europe was the largest region in the remicade biosimilar market in 2023. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

Major Driver Impacting Market Growth
The rise in the incidence of autoimmune diseases is expected to propel the growth of the remicade biosimilar market going forward. Autoimmune diseases are disorders in which the immune system mistakenly attacks and damages the body’s tissues and organs. Remicade biosimilars are used in treating autoimmune diseases by providing an effective therapeutic option to manage the symptoms and reduce inflammation associated with these. For instance, in October 2021, according to the reports shared by the City University of London, a UK-based public university, in the UK, 7%, or 4 million people, were suffering from autoimmune diseases by 2021, and over 80 autoimmune illnesses were identified with increasing prevalence annually by 3–9%. Furthermore, in July 2021, according to the Cleveland Clinic, a US-based, non-profit academic medical center, autoimmune diseases affected 1 in 15 people, with 1.4 million individuals having Crohn’s disease or ulcerative colitis, while 1 million people had lupus in 2021. Therefore, the rise in the incidence of autoimmune diseases is driving the growth of the Remicade biosimilar market.

Key Industry Players
Major companies operating in the remicade biosimilar market report are AbbVie Inc., Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Organon & Co., Merck And Co. Inc., Janssen Biotech Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvogen Inc, Synthon International Holding B.V., Coherus Biosciences Inc, Cardinal Health Inc, Genentech Inc., Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A

The remicade biosimilar market report table of contents includes:

1. Executive Summary
2. Remicade Biosimilar Market Characteristics
3. Remicade Biosimilar Market Trends And Strategies
4. Remicade Biosimilar Market – Macro Economic Scenario
5. Global Remicade Biosimilar Market Size and Growth
.
.
.
32. Global Remicade Biosimilar Market Competitive Benchmarking
33. Global Remicade Biosimilar Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Remicade Biosimilar Market
35. Remicade Biosimilar Market Future Outlook and Potential Analysis
36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model